FDA Inspection 1008063 — Piotr Serwatowski
The FDA completed an inspection of Piotr Serwatowski on Mar 10, 2017 in Szczecin. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Mar 10, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Szczecin (Poland)
Additional Details
Clinical Investigator (CI)